BioCentury
ARTICLE | Clinical News

Velicept's overactive bladder therapy meets in Phase IIb

March 29, 2019 6:50 PM UTC

Velicept said solabegron met the primary endpoint in the Phase IIb VEL-2002 trial to treat overactive bladder. The company plans to start a Phase III program of the next-generation adrenergic receptor β 3 (ADRB3) agonist early next year.

In 435 women ages 18-80 with OAB, twice-daily solabegron significantly reduced the mean number of daily micturitions from baseline to week 12 vs. placebo. Solabegron also met the secondary endpoints of reducing urge urinary incontinence episodes and urgency episodes vs. placebo. Detailed data were not disclosed...

BCIQ Company Profiles

Velicept Therapeutics Inc.